There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Estrogen receptor alpha (ERα) is a well-established therapeutic target for the treatment of
ER-positive (ER+) breast cancers. Despite the tremendous successes achieved with …

Rational development of targeted therapies has revolutionized metastatic breast cancer
outcomes, although resistance to treatment remains a major challenge. Advances in …

Breast cancer is a complex disease, and several processes are involved in its development.
Therefore, potential therapeutic targets need to be discovered for these patients …

The natural history of hormone receptor–positive breast cancer tends to be more favorable
than other subtypes such as human epidermal growth factor receptor 2–amplified and triple …

The estrogen receptor (ER) is an important driver in the proliferation, tumorigenesis, and
progression of breast cancers, and targeting ER signaling at different levels is a successful …

Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function
of lineage-specific and oncogenic transcription factors. Hyperactive FOXA1 signaling due to …

Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER
positive breast cancers. Selective modulation of ER has been a therapeutic target for this …

Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast
cancer (BC). Indeed, targeting the estrogen receptor (ER) signaling at different levels is a …

Abstract Purpose: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are
highly effective against estrogen receptor–positive (ER+)/HER2− breast cancer; however …